Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.

Cancer medicine - 1 Jul 2021

Jiang Kaili, Tang Xia, Guo Jing, He Rui, Chan Shingpan, Song Xiaojuan, Tu Zhengchao, Wang Yuting, Ren Xiaomei, Ding Ke, Zhang Zhang

Abstract excerpt

Abnormallyactivated FGFR1 has been validated as a therapeutic target for differentcancers. Although a variety of FGFR inhibitors have shown benefit in manyclinical patients with FGFR1 aberration, FGFR1 mutant resistance such as V561Mmutation, has been reported. To date however, no FGFR inhibitors have beenapproved to treat patients with FGFR mutant resistance. Herein, we report that GZD824, athird generation ABL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to G1 Phase Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Morpholines

Share to Phenylurea Compounds

Share to Quinoxalines

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, Fibroblast Growth Factor, Type 4

Source

Open in PubMed Open full text

Identifiers

PMID: 34114373
DOI: 10.1002/cam4.4041
PMCID: PMC8290231

Genes

FGFR1
F3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.PMID 34114373Read ↗

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read ↗

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.Semantic proximity Read ↗

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Semantic proximity Read ↗

FGFR families: biological functions and therapeutic interventions in tumorsSemantic proximity Read ↗

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesSemantic proximity Read ↗

Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors.Semantic proximity Read ↗

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.Semantic proximity Read ↗

Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.Semantic proximity Read ↗

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.Semantic proximity Read ↗

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesSemantic proximity Read ↗

Targeting FGFR1 to suppress leukemogenesis in syndromic and <i>de novo</i> AML in murine modelsSemantic proximity Read ↗

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.